Short‐term visual acuity between 20/20 and 20/40 ≤ 2 weeks after treatment; oral corticosteroids · people with traumatic hyphema
Systemic or topical corticosteroids showed no clear difference in short‐term visual acuity between 20/20 and 20/40 ≤ 2 weeks after… compared with placebo or control treatment (low certainty).
1 finding from 1 review
Final visual acuity between 20/20 and 20/40 at end of treatment; oral corticosteroids · people with traumatic hyphema
Systemic or topical corticosteroids showed no clear difference in final visual acuity between 20/20 and 20/40 at end of treatment;… compared with placebo or control treatment (low certainty).
1 finding from 1 review
Short‐term visual acuity between 20/20 and 20/40 ≤ 2 weeks after treatment; topical corticosteroids · people with traumatic hyphema
It is very uncertain whether systemic or topical corticosteroids changes short‐term visual acuity between 20/20 and 20/40 ≤ 2 weeks after… compared with placebo or control treatment (very low certainty).
1 finding from 1 review
Final visual acuity between 20/20 and 20/25 at end of treatment; topical corticosteroids · people with traumatic hyphema
Systemic or topical corticosteroids showed no clear difference in final visual acuity between 20/20 and 20/25 at end of treatment;… compared with placebo or control treatment (low certainty).
1 finding from 1 review
Clinical improvement (dichotomous) · active EoE patients
Corticosteroids may leads to higher clinical improvement (dichotomous) compared with placebo (low certainty).
1 finding from 1 review
Histological improvement (dichotomous) · inactive EoE patients
Corticosteroids probably leads to higher histological improvement (dichotomous) compared with placebo (moderate certainty).
1 finding from 1 review
Histological improvement (continuous) · inactive EoE patients
1 finding from 1 review
Endoscopic improvement (dichotomous) · inactive EoE patients
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Endoscopic improvement (continuous) · inactive EoE patients
1 finding from 1 review
Withdrawals due to adverse events · inactive EoE patients
Corticosteroids may leads to lower withdrawals due to adverse events 12 to 50 weeks compared with placebo (low certainty).
1 finding from 1 review
Clinical improvement (continuous) · active EoE patients
1 finding from 1 review
Histological improvement (dichotomous) · active EoE patients
Corticosteroids leads to higher histological improvement (dichotomous) compared with placebo (high certainty).
1 finding from 1 review
Histological improvement (continuous) · active EoE patients
1 finding from 1 review
Endoscopic improvement (dichotomous) · active EoE patients
Corticosteroids showed no clear difference in endoscopic improvement (dichotomous) compared with placebo (low certainty).
1 finding from 1 review
Endoscopic improvement (continuous) · active EoE patients
1 finding from 1 review
Withdrawals due to adverse events · active EoE patients
Corticosteroids may leads to lower withdrawals due to adverse events (2 to 12 weeks) compared with placebo (low certainty).
1 finding from 1 review
Clinical improvement (dichotomous) · inactive EoE patients
It is very uncertain whether corticosteroids changes clinical improvement (dichotomous) compared with placebo (very low certainty).
1 finding from 1 review
Clinical improvement (continuous) · inactive EoE patients
1 finding from 1 review
Time to resolution of primary hemorrhage · people with traumatic hyphema
2 findings from 1 review
Risk of secondary hemorrhage; oral corticosteroids · people with traumatic hyphema
Systemic or topical corticosteroids may leads to lower risk of secondary hemorrhage; oral corticosteroids compared with placebo or control treatment (low certainty).
1 finding from 1 review